HENDERSON, Nev., April 11, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) published a report on the therapeutic effect and potential economic impact of ITV-1. The document contains the company’s findings on the effects of the drug on volunteers suffering from AIDS, cancer and ot
HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) presents projected revenue for each market with exclusive distribution agreement. NIKA has previously reported an estimated potential €7.9 billion in revenue from its distribution agreement in Nigeria1. Wit
HENDERSON, Nev., June 03, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders. To achieve its goals, NIKA will wo
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is a SEC reporting Colorado corporation dedicated to the development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs.
